Moleculin Biotech Files 2024 Annual Report Amendment
Ticker: MBRX · Form: 10-K/A · Filed: Apr 18, 2025 · CIK: 1659617
| Field | Detail |
|---|---|
| Company | Moleculin Biotech, Inc. (MBRX) |
| Form Type | 10-K/A |
| Filed Date | Apr 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, annual-report, pharmaceuticals
Related Tickers: MBRX
TL;DR
Moleculin Biotech (MBRX) filed its amended 2024 10-K. Check for updates.
AI Summary
Moleculin Biotech, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The filing, dated April 18, 2025, provides updated information for the company, which is in the pharmaceutical preparations industry. The company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, Texas.
Why It Matters
This amendment to the annual report provides updated financial and operational information for investors and stakeholders, reflecting the company's status as of December 31, 2024.
Risk Assessment
Risk Level: low — This filing is an amendment to a standard annual report and does not appear to contain significant new negative information.
Key Numbers
- 2024 — Fiscal Year End (The report covers the fiscal year ending December 31, 2024.)
- 001-37758 — SEC File Number (This is the company's assigned SEC file number.)
Key Players & Entities
- Moleculin Biotech, Inc. (company) — Registrant
- 2024 (date) — Fiscal Year End
- April 18, 2025 (date) — Filing Date
- 5300 Memorial Drive, Suite 950, Houston, Texas 77007 (address) — Principal Executive Offices
FAQ
What specific changes or updates are detailed in this 10-K/A amendment?
The filing is an amendment to the annual report for the fiscal year ended December 31, 2024, indicating updates to previously filed information, though the specific details of the changes are not provided in this excerpt.
When was the original 10-K filed, and what is the purpose of this amendment?
The original 10-K was for the fiscal year ended December 31, 2024. This 10-K/A (Amendment No. 1) was filed on April 18, 2025, to amend or supplement the original filing.
What is Moleculin Biotech, Inc.'s primary business activity?
Moleculin Biotech, Inc. is classified under the Standard Industrial Classification code 2834, which corresponds to Pharmaceutical Preparations.
Where is Moleculin Biotech, Inc. headquartered?
The company's principal executive offices are located at 5300 Memorial Drive, Suite 950, Houston, Texas 77007.
What is the SEC file number for Moleculin Biotech, Inc.?
The SEC file number for Moleculin Biotech, Inc. is 001-37758.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on April 18, 2025 regarding Moleculin Biotech, Inc. (MBRX).